PUSH Plus Protein Pilot for Hip Fracture Patients



Status:Recruiting
Conditions:Orthopedic, Orthopedic
Therapuetic Areas:Orthopedics / Podiatry
Healthy:No
Age Range:60 - Any
Updated:10/14/2018
Start Date:July 16, 2018
End Date:December 2020
Contact:Denise Orwig, PhD
Email:dorwig@som.umaryland.edu
Phone:410-706-2406

Use our guide to learn which trials are right for you!

Community Ambulation Project (CAP) Ancillary Study - PUSH Plus Protein Pilot Study

Hip fracture is a common problem among older individuals. The goal of current standard of
care after hip fracture is to achieve independent, household ambulation 2-3 months after
surgery, yet decreased functional ability typically persists well beyond three months and
many patients never resume independent ambulation outside the home. Previous research has
established that one must be able to walk at least 300 meters (~330 yards) within 6 minutes
to re-establish routine interactions in the community, such as going to the store or to
church. In part, this is based on the average distance from handicapped parking spaces into
most facilities. Activity and exercise are believed to be of benefit for reducing disability
in older adults, yet the majority of older adults does not participate in regular exercise
and is not active. This is especially true for older adults following hip fracture after they
complete the usual rehabilitation program.

This research study is being done to test a 16-week, multi-part exercise intervention for hip
fracture patients that will be supervised by specially trained physical therapists (PTs). The
exercise intervention uses a novel machine to provide strength and endurance training in the
home. This has been shown in smaller studies to be safe and effective at increasing strength.
The purpose of this small pilot study is to test whether adding a protein supplement to the
exercise intervention leads to more improvements in a person's ability to walk in their own
home and in the local community. With this knowledge, investigators hope to help a greater
number of hip fracture patients enjoy a more complete recovery and improved overall health.

In addition to providing important information on adherence, feasibility, and safety, this
pilot study of hip fracture patients has the unique advantage of being able to compare data
to two recently completed studies where participants received the PUSH intervention without
protein supplementation.

A pilot study including 30 older adults who have experienced a hip fracture will be carried
out with participants receiving a specific multi-component intervention with protein
supplementation (PUSH Plus Protein). Study activities for participants meeting eligibility
criteria will take place after post-acute rehabilitation ends, up to 26 weeks after admission
to the hospital for hip fracture. Patients age 60 and older who have had surgical repair for
hip fracture will be identified in study hospitals or by self-referral and evaluated for
eligibility. Following consent to participate, eligible participants will undergo a
comprehensive baseline assessment. Participants completing the entire baseline assessment
will be eligible to receive the intervention. All participants will receive the PUSH Plus
Protein intervention. The follow-up assessment will occur after the intervention is
completed, approximately 16 weeks after baseline testing. The primary endpoint will be
measured using the Six-Minute Walk Test (SMWT).

Participants in this pilot will receive the same specific multi-component 16-week
intervention, PUSH, as participants in the multi-site randomized controlled trial, "Improving
Community Ambulation after Hip Fracture (CAP)" (NCT01783704). The purpose of this study is to
test whether adding a protein supplement to the PUSH intervention (PUSH Plus Protein) leads
to greater improvement in a person's ability to walk in their own home and in the local
community compared to the PUSH intervention alone; therefore, data in this pilot study will
be compared to data from participants in the CAP study across the three sites who received
the PUSH intervention alone (n=105). The working hypothesis is that PUSH Plus Protein will
lead to greater improvements in ability to walk in the community compared to PUSH.

Investigators will also compare the effect of PUSH Plus Protein intervention to PUSH
intervention alone on secondary outcomes in the CAP study believed to be precursors to
community ambulation as shown in Aim 2 below.

Investigators can also compare participants in the pilot study to participants who received
PUSH alone in the ancillary study to CAP, "Mechanistic Pathways to Community Ambulation
(CAP-MP)" (n=19) to examine whether PUSH Plus Protein has an impact on the mechanistic
factors on the pathway to recovery of ambulatory ability after hip fracture (Aim 3).

Aim 1. To test whether PUSH Plus Protein intervention improves community ambulation (as
measured by distance walked in six minutes) compared to PUSH intervention alone (from CAP
parent study) at the end of 16 weeks.

Aim 2. To assess the effects of PUSH Plus Protein on precursors to community ambulation
compared to the PUSH intervention alone (CAP study). To determine the effects of PUSH Plus
Protein intervention, compared to PUSH, on several other outcomes in CAP including activities
of daily living (ADLs), quality of life, lower-extremity physical performance, increase of ≥
50 meters in distance walked in six minutes, cognitive status, and nutritional status.

Aim 3. To determine the effects of PUSH Plus Protein intervention on the mechanistic factors
compared to PUSH intervention alone (CAP-MP ancillary study). To determine if, at the end of
the 16 week intervention, participants in the PUSH Plus Protein intervention, compared to
PUSH alone, have: a) greater muscle volume and attenuation (i.e., reduced intra-muscular fat)
of the thigh; b) greater lower extremity strength; c) better gait parameters; d) greater bone
mineral density and bone strength; e) more bone formation and less bone resorption; and f)
lower levels of circulating inflammatory cytokines.

Aim 4. To determine safety and tolerability of delivering the PUSH Plus Protein intervention
to hip fracture patients. This pilot study will be used to estimate the sample size
requirements for a more definitive study.

Inclusion Criteria:

- Closed fracture of proximal femur

- Age 60 or older at time of baseline testing

- Minimal trauma fracture

- Non-pathologic fracture

- Surgical fixation of fracture

- Living in the community at time of fracture

- Ambulating without human assistance 2 months prior to fracture

- Unable to walk 300 m or more in 6 minutes without human assistance at time of baseline
testing

Exclusion Criteria:

- Not English speaking

- Does not live within reasonable distance of the clinical center

- End stage renal disease on dialysis

- Recent myocardial infarction

- Uncompensated congestive heart failure

- Lower extremity amputation

- Symptoms of angina pectoris

- Chest pain or shortness of breath (including from severe COPD)

- Participant plans to move out of area or otherwise be unavailable during the 16-week
intervention period

- Participation in another clinical trial

- Not community-residing (e.g., resident of a skilled nursing facility) at time of
baseline testing

- Not fully weight-bearing on fractured leg or non-fractured leg at time of baseline
testing

- Calculated creatinine clearance < 15 ml/min

- Serum albumin < 2.5 g/dl

- Hemoglobin < 9 g/dl

- Receiving physical therapy for the hip fracture in the hospital or inpatient
rehabilitation facility at time of baseline testing

- Severely diminished lower extremity sensation or ulceration

- Uncontrolled hypertension

- Chronic kidney disease

- Severe liver disease (e.g., hepatitis, fatty liver disease, cirrhosis)

- Poorly controlled and/or insulin-dependent diabetes

- Known dairy allergy

- Denied medical clearance by appropriate medical provider

- Clinical site clinician thinks participant is not a good candidate for study (e.g.,
not likely to survive study period)

- Cognitive impairment (3MS score <73)

- Development of chest pain or substantial shortness of breath or ambulating with severe
pain during baseline SMWT

- Participant walks less than 4 meters in 40 seconds (<0.1 m/sec) during baseline SMWT

- Baseline testing not done by 26 weeks post admission for hip fracture

- Final sign-off from study clinician and/or principal investigator is incomplete

- Incomplete baseline data

- Unable to contact participant

- Participant is unable to provide her/his own informed consent

- Participant refuses the study
We found this trial at
2
sites
?
mi
from
Towson, MD
Click here to add this to my saved trials
621 West Lombard Street
Baltimore, Maryland 21201
(410) 706-7101
University of Maryland, Baltimore Welcome to the University of Maryland, Baltimore (UMB) founded in 1807...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials